Protara Therapeutics KUV 2024

Šta radi Protara Therapeutics?

Protara Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for rare and severe immune system disorders. It was founded in 2012 and is based in Tarrytown, New York. The company was formed through the merger of NeuroproteXeon, Inc. and Biokine Therapeutics Ltd, with the goal of developing a pipeline of novel therapeutics for rare immune system diseases. In 2018, the company was acquired by Protea Biosciences Group Inc. Protara's business model revolves around the discovery, development, and commercialization of innovative therapeutics for immune system disorders. The company utilizes various technologies and platforms, including its proprietary protein engine, to drive its innovation program. It currently has two main divisions: one focused on the development and commercialization of T-cell-engaging Bi-Specifics, a novel class of immunotherapeutics specialized in tumor antigen-specific T-cell activation, and another division offering innovative nanotechnology platforms for the development of drugs for the treatment of inflammatory and immune disorders. Protara's leading pipeline products include TULIP Bi-Specific (JNJ-63898081), a T-cell-engaging Bi-Specific against CD3 and BCMA in phase I/IIa clinical trials for patients with multiple myeloma, and RTX-240, a T-cell-engaging Bi-Specific against CD3 and PSMA in the development phase for patients with advanced solid tumors. The company also focuses on developing precursor molecules for T-cell-engaging Bi-Specifics and protein engineering and optimization technologies to enhance the effectiveness and half-life of immunotherapeutics. Additionally, Protara has proprietary nanoparticle platforms, known as NANOMAbs, with promising applications in the treatment of inflammatory and immune disorders such as COVID-19, lupus, dermal diseases, and others. In summary, Protara Therapeutics Inc is a leading biopharmaceutical company focused on innovative therapies for immune system disorders. Its pipeline includes T-cell-engaging Bi-Specifics and proprietary nanoparticle platforms with promising applications in the treatment of inflammatory and immune disorders. With its complex technology and protein development and optimization capabilities, Protara continues to create groundbreaking new treatment options for patients. Protara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.